Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers in a Randomised, Double-blind, Placebo-controlled Design.

Trial Profile

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers in a Randomised, Double-blind, Placebo-controlled Design.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs BI 691751 (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 19 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Mar 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
    • 14 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top